Femoral fixture for a hip joint prosthesis
Latest AstraZeneca AB Patents:
- Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as GLP-1 receptor modulators
- N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides
- Automated assessment of wound tissue
- Inhibitors of myeloperoxidase
- Therapeutic combinations of acalabrutinib and capivasertib to treat B-cell malignancies
Description
FIG. 1 is a top perspective view of a femoral fixture for a hip joint prosthesis showing our new design;
FIG. 2 is a bottom perspective view thereof;
FIG. 3 is a side elevational view thereof;
FIG. 4 is a top plan view thereof; and,
FIG. 5 is a bottom plan view thereof.
Claims
The ornamental design for a femoral fixture for a hip joint prosthesis, as shown and described.
Referenced Cited
U.S. Patent Documents
Foreign Patent Documents
Other references
| 5980575 | November 9, 1999 | Albrektsson et al. |
| 9725939 | July 1997 | WO |
- U.S. application No. 08/776,987, Albrektsson et al., filed Feb. 18, 1997.
Patent History
Patent number: D455212
Type: Grant
Filed: Apr 4, 2001
Date of Patent: Apr 2, 2002
Assignee: AstraZeneca AB (Sodertalje)
Inventors: Thomas Albrektsson (Molndal), Magnus Jacobsson (Gothenburg), Stig Wennberg (Gunnilse), Lars Carlsson (Kullavik), Warren Macdonald (Boscombe)
Primary Examiner: Antoine Duval Davis
Attorney, Agent or Law Firm: White & Case LLP
Application Number: 29/139,717
Type: Grant
Filed: Apr 4, 2001
Date of Patent: Apr 2, 2002
Assignee: AstraZeneca AB (Sodertalje)
Inventors: Thomas Albrektsson (Molndal), Magnus Jacobsson (Gothenburg), Stig Wennberg (Gunnilse), Lars Carlsson (Kullavik), Warren Macdonald (Boscombe)
Primary Examiner: Antoine Duval Davis
Attorney, Agent or Law Firm: White & Case LLP
Application Number: 29/139,717
Classifications
